MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Merck & Co., Inc., Rahway, NJ, USA (United States)
Abstract
The serine/threonine kinase Akt lies at a critical signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis. An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is associated with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors. We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents. In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with molecular targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal…
Citation impact
- FWCI
- 24.50
- Percentile
- 100%
- References
- 53
Authors
11- HHHiroshi HiraiCorresponding
Merck & Co., Inc., Rahway, NJ, USA (United States)
- HSHiroshi Sootome
Merck & Co., Inc., Rahway, NJ, USA (United States)
- YNYoko Nakatsuru
Merck & Co., Inc., Rahway, NJ, USA (United States)
- KMKatsuyoshi Miyama
Merck & Co., Inc., Rahway, NJ, USA (United States)
- STShunsuke Taguchi
Merck & Co., Inc., Rahway, NJ, USA (United States)
Topics & keywords
- Erlotinib
- Protein kinase B
- Pharmacology
- Epidermal growth factor receptor
- Cancer research
- Chemistry
- Biology
- Signal transduction
- Good health and well-being